Funder: National Institutes of Health

Due Dates: June 20, 2025 (New/Renewal/Resubmission/Revision) | February 20, 2026 (New/Renewal/Resubmission/Revision) | June 22, 2026 (New/Renewal/Resubmission/Revision)

Funding Amounts: Up to $700,000 total costs/year (Phase I, max 2 years) | Up to $1,500,000 total costs/year (Phase II, max 3 years)

Summary: Supports rigorous clinical validation of strong candidate biomarkers for neurological or neuromuscular disorders, with the goal of establishing predictive values in clinical populations.

Key Information: Only U.S. small businesses (SBIR) are eligible; biomarker and detection method must already be identified and analytically validated.